{"filings":[{"id":2577956,"accession_number":"0001477449-26-000044","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-08-31T20:35:08+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc names Michael Grasher CFO; base salary $550K, $500K sign-on bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Grasher appointed CFO effective Aug 31, 2026; prior CFO of IFG Companies, Fortegra, AMERISAFE.","Compensation: $550K base salary, $500K sign-on bonus, 85% target bonus from 2027.","New-hire equity award ~$3M under 2023 Inducement Plan (50% RSUs, 50% PSUs) expected Sept 1, 2026.","Charles Divita, III continues as CEO; Grasher brings 12+ years CFO experience and public markets background."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2243916,"accession_number":"0001477449-26-000042","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-08-13T20:05:07+00:00","items":["5.02"],"status":"ready","headline":"Teladoc director David B. Snow Jr. to retire from board effective Sept 30, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David B. Snow Jr. notified Teladoc on Aug 10, 2026 of his retirement from the Board.","Retirement effective September 30, 2026; Snow has served as director since 2014.","Snow stated he is retiring for personal reasons, not due to any disagreement with the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":2025197,"accession_number":"0001477449-26-000040","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-08-03T20:31:02+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc Health appoints former Verisk president Mark Anquillare to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark V. Anquillare appointed to Teladoc Health board effective August 3, 2026.","Anquillare served as Verisk Analytics president and COO; previously CFO from 2007.","He will serve on the audit and compensation committees.","Board expanded to ten members; Anquillare deemed independent and an audit committee financial expert.","Anquillare also serves on Guidewire Software board (audit chair) and RegEd, Bamboo Insurance boards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1940563,"accession_number":"0001477449-26-000036","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-07-29T20:05:47+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q2 revenue down 4% to $606.9M; BetterHelp segment revenue falls 12%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.9M ($0.21 per share) vs $32.7M loss a year ago; adjusted EBITDA $65.7M, down 5%.","Integrated Care revenue +1% to $394.3M; BetterHelp revenue -12% to $212.6M on cash pay pressure.","BetterHelp insurance rollout accelerated; cash pay decline exceeded prior assumptions, lowering segment outlook.","Full year 2026 guidance: revenue $2,362-$2,447M, adjusted EBITDA $271-$303M; Q3 revenue $569-$609M.","Free cash flow Q2 $35.7M vs $61.2M a year ago; full year FCF guidance $130-$170M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581756,"accession_number":"0001477449-26-000030","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-05-21T20:04:53+00:00","items":["5.07"],"status":"ready","headline":"Teladoc Health holds 2026 annual meeting; all director nominees elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All eight director nominees elected; David B. Snow, Jr. received 67.4M for (12.9M against).","Advisory say-on-pay approved with 71.2M for, 9.0M against, 1.2M abstain.","Ratification of EY as auditor approved with 122.6M for, 1.2M against.","Broker non-votes of 43.2M on director elections and say-on-pay; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93078,"accession_number":"0001477449-26-000026","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Health Q1 2026 Revenue Falls 2% to $613.8M, Net Loss Narrows to $63.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First Quarter 2026 revenue of $613.8 million, down 2% year-over-year","Net loss improved to $63.8 million ($0.36 per share) from $93.0 million ($0.53 per share) in prior year","Adjusted EBITDA was $58.2 million, essentially flat year-over-year","Integrated Care segment revenue up 2% to $395.4 million; BetterHelp down 9% to $218.4 million","Company reaffirmed full-year 2026 outlook with revenue range $2.481B-$2.576B and adjusted EBITDA $267M-$306M"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":613845000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104405,"accession_number":"0001477449-26-000016","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc Health appoints Susan Salka, ex-AMN Healthcare CEO, to its board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Salka appointed to Teladoc board effective March 30, 2026; will serve on audit and compensation committees.","She is former president and CEO of AMN Healthcare, with 33-year tenure; oversaw growth to $5B revenue.","Board expanded to nine members; Salka succeeds retiring directors Eric Evans and Thomas McKinley; Michael Smith previously appointed.","Salka is independent director and qualifies as audit committee financial expert under NYSE/SEC rules.","She currently serves on board of Parexel International and previously served on McKesson, Beckman Coulter, Playtex boards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104404,"accession_number":"0001477449-26-000010","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q4 revenue flat at $642M, net loss narrows; FY2026 revenue guidance $2.47-2.587B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $642.3M (flat YoY); net loss $25.1M vs $48.4M loss; adjusted EBITDA $83.8M (+12% YoY).","Full year 2025 revenue $2.53B (-2% YoY); net loss $200.3M vs $1.001B loss (lower goodwill impairment).","Integrated Care segment revenue +5% in Q4; BetterHelp -7%. FY Integrated Care adjusted EBITDA +3% to $239.2M.","FY2026 revenue guidance $2.47-2.587B; adjusted EBITDA $266-308M; free cash flow $130-170M.","Cash and equivalents $781.1M at year-end; Q4 free cash flow $53.4M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":2529977000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104403,"accession_number":"0001477449-26-000004","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc appoints Michael Smith, former Voya Financial CFO, to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment of Michael Smith to board effective Feb 18, 2026; board size temporarily expanded to 10.","Smith served as Vice Chair and CFO of Voya Financial; brings over 30 years in financial services.","He will serve on audit and nominating/corporate governance committees.","Appointment follows previously announced retirements of directors Eric Evans and Thomas McKinley.","Teladoc to report Q4 2025 results on Feb 25, 2026, after market close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104402,"accession_number":"0001477449-26-000002","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Thomas G. McKinley to retire from Teladoc Health board effective Feb 20, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas G. McKinley, a director since 2009, notified Teladoc of his retirement effective Feb 20, 2026.","Retirement is for personal reasons and not due to any disagreement with the Company.","The Company thanked him for his dedicated service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120700,"accession_number":"0001477449-25-000126","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teladoc director J. Eric Evans to retire at 2026 Annual Meeting, not standing for reelection","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Eric Evans notified Teladoc on Dec 11, 2025 of intention not to stand for reelection at the 2026 Annual Meeting.","He will retire from the Board effective as of the conclusion of the 2026 Annual Meeting.","Evans has been a director since 2023, leaving for personal reasons; no disagreement with the company.","No replacement has been named at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120699,"accession_number":"0001477449-25-000122","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Teladoc Health increases inducement plan share reserve by 1.78M shares to 7.28M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amendment effective Dec 9, 2025 to increase share reserve by 1,780,000 shares to total 7,280,000 shares under 2023 Inducement Plan.","Plan is used for equity awards to new employees as inducements without stockholder approval per NYSE Rule 303A.08.","Amendment filed as Exhibit 10.1; no other changes to Plan terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120698,"accession_number":"0001477449-25-000117","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q3 revenue down 2% to $626.4M; net loss widens to $49.5M; adj. EBITDA falls 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $626.4M (-2% YoY); net loss $49.5M ($0.28 per share) vs. $33.3M loss a year ago.","Adjusted EBITDA $69.9M (-16% YoY); Integrated Care segment rev +2% to $389.5M; BetterHelp rev -8% to $236.9M.","Full-year 2025 guidance: revenue $2.51B-$2.539B; adj. EBITDA $270M-$287M; net loss per share ($1.25)-($1.10).","Cash from ops $99.3M in Q3; free cash flow $67.9M vs. $79.0M a year ago.","Non-cash goodwill impairment of $12.6M in Q3; $17.0M stock-based comp; $85.8M amortization intangibles."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1887708000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120697,"accession_number":"0001477449-25-000114","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Teladoc Health CFO Mala Murthy resigns; preliminary Q3 revenue $626.4M, adj EBITDA $69.9M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Mala Murthy to resign effective Nov 21, 2025; interim finance leaders reporting to CEO.","Preliminary Q3 2025 consolidated revenue $626.4M, adjusted EBITDA $69.9M (unaudited).","Full-year 2025 consolidated revenue and adjusted EBITDA outlook reaffirmed (from July 29).","CFO search initiated; Murthy will present on Q3 earnings call Oct 29.","No GAAP EPS or segment details provided; full results to be released Oct 29."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137291,"accession_number":"0001477449-25-000096","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q2 revenue $631.9M (-2% YoY); adjusted EBITDA $69.3M (-23%); retires $550.6M convertible notes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $32.7M ($0.19 per share), improved from $837.7M loss in Q2 2024 which included $790M goodwill impairment.","Integrated Care segment revenue $391.5M (+4% YoY); BetterHelp revenue $240.4M (-9% YoY).","Paid $550.6M cash to retire convertible notes; entered a five-year $300M secured revolving credit facility on July 17.","Full-year 2025 revenue guidance $2,501–$2,548M; adjusted EBITDA $263–$294M; Q3 revenue guidance $614–$636M.","Free cash flow $61.2M in Q2 vs. $60.9M in Q2 2024; Capex $30.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":1261269000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137290,"accession_number":"0001477449-25-000091","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teladoc Health enters $300M senior secured revolving credit facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year $300M senior secured revolver with JPMorgan Chase as administrative agent; no immediate borrowings planned.","Interest rates: SOFR + 2.75%-3.25% or base rate + 1.75%-2.25%, based on secured net leverage ratio.","Financial covenants: max secured net leverage 3.50:1 (4.00:1 after certain acquisitions) and min interest coverage 3.00:1.","Proceeds to preserve financial flexibility; capital allocation priorities unchanged (balance sheet, organic/inorganic growth, share repurchases).","Obligations secured by substantially all assets of Teladoc and material domestic/foreign subsidiaries."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154599,"accession_number":"0001477449-25-000063","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Teladoc shareholders approve 6.85M share increase for incentive plan; say-on-pay passes with 26.6% against","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2023 Incentive Award Plan, increasing authorized shares by 6,850,000.","All nine director nominees elected; David B. Snow Jr. received 19.9M against (23.9% against) and Kenneth Paulus received 10.9M against (13.1% against).","Advisory vote on executive compensation passed: 61.2M for, 22.2M against (26.6% against).","Ratification of Ernst & Young as independent auditor for FY2025 approved with 119.9M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154598,"accession_number":"0001477449-25-000047","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q1 revenue down 3% to $629M; net loss widens on $59M goodwill impairment; acquires UpLift","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $629.4M (-3% YoY); net loss $93M ($0.53/sh) includes $59.1M goodwill impairment.","Integrated Care rev $389.5M (+3%), adj EBITDA margin 12.9%; BetterHelp rev $239.9M (-11%), adj EBITDA margin 3.2%.","Completed acquisition of UpLift Health for $30M cash plus up to $15M earnout; adds 100M+ covered lives.","FY 2025 outlook: rev $2.468-$2.576B, adj EBITDA $263-$304M, free cash flow $170-$200M.","Q2 2025 guidance: rev $614-$633M, adj EBITDA $56-$70M; BetterHelp rev expected to decline 7.5%-11.25% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":629369000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173132,"accession_number":"0001477449-25-000002","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Health Q4 revenue $640.5M (-3% YoY); full-year net loss $1.0B on $790M goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $640.5M (-3% YoY); full-year revenue $2,569.6M (-1% YoY).","Q4 net loss $48.4M ($0.28/share); full-year net loss $1,001.2M ($5.87/share) includes $790M non-cash goodwill impairment in BetterHelp.","Q4 adjusted EBITDA $74.8M (-35% YoY); full-year adjusted EBITDA $310.7M (-5% YoY).","Integrated Care segment revenue +2% in Q4; BetterHelp segment revenue -10% in Q4, segment weakness persists.","2025 guidance: revenue $2,468-2,576M, adj. EBITDA $278-319M, net loss per share ($1.10)-($0.50); includes Catapult Health acquisition expected close Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":2569574000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190157,"accession_number":"0001477449-24-000224","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q3 revenue $640.5M (-3% YoY), net loss narrows to $0.19 EPS; BetterHelp revenue down 10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $640.5M (-3% YoY); net loss $33.3M ($0.19 per share) vs $57.1M loss last year.","Adjusted EBITDA $83.3M (-6% YoY); Integrated Care margin 17.7%, BetterHelp margin 5.9%.","BetterHelp revenue down 10% to $256.8M; nine-month goodwill impairment of $790M recorded.","Free cash flow $79.0M in Q3 vs $68.0M YoY; operating cash flow $110.2M.","Guidance: Integrated Care Q4 revenue growth 0-2.5%, FY24 adj. EBITDA margin ~15%."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1929083000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190156,"accession_number":"0001477449-24-000216","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teladoc Health COO Michael Waters resigns effective Dec 31, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO Michael Waters resigns with good reason due to change in executive reporting structure.","Resignation effective at close of business on December 31, 2024.","Severance includes 9 months base salary, COBRA premiums, 2024 bonus, and accelerated vesting of equity scheduled to vest within 9 months.","Conditions: remain employed through separation, sign release, and comply with 9-month non-compete and non-solicit.","Company thanks Mr. Waters for his service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206664,"accession_number":"0001477449-24-000200","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teladoc Health appoints Joseph Catapano as SVP and Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Catapano joined Teladoc as SVP and Chief Accounting Officer effective Sept 9, 2024.","Previously VP and CAO of Pitney Bowes (Aug 2017–Sept 2024); served as Interim CFO there.","Compensation: $375k base salary, $100k sign-on bonus, annual bonus target 40% of base, guaranteed 2024 bonus $150k.","Received 25,000 RSUs; 1/3 vests on first anniversary, rest quarterly starting 15 months post-grant.","Eligible for Level 13 Severance Plan; subject to one-year non-compete and non-solicitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206663,"accession_number":"0001477449-24-000172","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q2 revenue down 2% to $642.4M; net loss $837.7M on $790M goodwill impairment; FY outlook withdrawn","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $642.4M (-2% YoY); net loss $837.7M ($4.92/sh) includes $790M goodwill impairment for BetterHelp.","Adjusted EBITDA $89.5M (+24% YoY); Integrated Care +5% to $377.4M, BetterHelp -9% to $265.0M.","Company withdraws FY2024 consolidated and BetterHelp outlook and three-year outlook; provides Integrated Care guidance only.","New CEO Chuck Divita joined; comments on strengthening execution and streamlining organization.","Cash from operations $88.7M; free cash flow $60.9M; capex $27.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":1288575000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206662,"accession_number":"0001477449-24-000168","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teladoc Health terminates President Laizer Kornwasser without cause, effective July 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laizer Kornwasser, President of Enterprise Growth and Global Markets, terminated without cause; effective July 1, 2024.","He will serve as Advisor to CEO until August 2, 2024, then depart.","Severance per Executive Employment Agreement dated October 24, 2022.","No replacement named; change in executive reporting structure cited."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223847,"accession_number":"0001477449-24-000157","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc Health names Chuck Divita as CEO effective June 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Charles Divita appointed CEO and board member; Mala Murthy returns to CFO role.","Divita previously EVP Commercial Markets at GuideWell/Florida Blue, overseeing $23B in revenue.","New-hire equity award valued at ~$15M: 939,849 PSUs and 469,924 RSUs; base salary $800,000.","Company amended 2023 Inducement Plan, increasing reserved shares by 4M to 4.5M for CEO grants.","Mala Murthy's severance agreement amended to provide two years of enhanced severance protections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223846,"accession_number":"0001477449-24-000122","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Teladoc Health reports 2024 annual meeting voting; all director nominees elected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; votes for ranged from 74.9M to 88.2M.","Say-on-pay approved with 86.0M for (95.9% of votes cast); 3.7M against.","Stockholders voted for 1-year frequency on future advisory votes (84.6M for one year).","Ratification of Ernst & Young as auditor passed with 119.5M for, 2.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223845,"accession_number":"0001477449-24-000099","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Health Q1 revenue +3% to $646.1M; adjusted EBITDA +20% to $63.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $646.1M (+3% YoY); net loss $81.9M ($0.49 EPS) vs $69.2M loss in Q1 2023.","Integrated Care revenue +8% to $377.1M; BetterHelp revenue -4% to $269.0M.","Adjusted EBITDA rose 20% to $63.1M; free cash flow -$26.6M (improved from -$32.5M).","Q2 2024 outlook: revenue $635-660M, adj. EBITDA $70-80M, net loss per share ($0.45)-($0.35).","Full-year 2024 outlook: revenue $2,635-2,735M, adj. EBITDA $350-390M, FCF $210-240M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":646131000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223844,"accession_number":"0001477449-24-000094","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teladoc Health CAO Richard Napolitano resigns, effective May 3, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Napolitano leaves to pursue another career, no disagreement with company.","James L. Cave, VP Corporate Controller, appointed interim Chief Accounting Officer.","Cave to receive $100,000 in one-time bonuses for assuming interim role.","Cave has been with Teladoc since October 2021; prior roles at CMC Materials, Donnelly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223843,"accession_number":"0001477449-24-000083","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Teladoc CEO Jason Gorevic departs; CFO Mala Murthy named acting CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Gorevic departs immediately; Board retains search firm for permanent successor.","CFO Mala Murthy appointed acting CEO, retains CFO role; base salary raised to $750k, target bonus 120%, additional equity $1.1M.","Company reaffirms Q1 2024 and full-year 2024 guidance, consistent with Feb 20 earnings release.","Gorevic eligible for separation benefits per employment agreement subject to release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243246,"accession_number":"0001477449-24-000017","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q4 2023 revenue $660.5M, adj. EBITDA up 22% to $114.4M; guides FY2024 revenue $2.64-2.74B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $660.5M (+4% YoY); Full year revenue $2,602.4M (+8% YoY).","Q4 net loss $28.9M ($0.17/sh) vs $3.81B loss a year ago; FY net loss $220.4M ($1.34/sh).","Q4 adjusted EBITDA $114.4M (+22% YoY); FY adj. EBITDA $328.1M (+33% YoY); FY free cash flow $193.7M.","FY2024 guidance: revenue $2,635-2,735M, adj. EBITDA $350-390M, free cash flow $210-240M.","Efficiency program targets ~$43M net expense reduction in 2024; expects $85M annualized savings."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":2602415000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260642,"accession_number":"0001477449-23-000076","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teladoc Health Chief Innovation Officer Claus Jensen resigns; receives $743,750 separation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Claus Jensen resigns as Chief Innovation Officer effective December 1, 2023.","Cash separation payment of $743,750 (6 months salary plus 75% of target 2023 bonus).","Accelerated vesting of time-based equity awards vesting on or before December 2, 2024.","Continued eligibility for performance-based awards through December 31, 2023.","Up to 6 months COBRA premium coverage; 12-month non-compete and non-solicit obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260641,"accession_number":"0001477449-23-000063","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q3 revenue up 8% to $660.2M; adjusted EBITDA surges 73% to $88.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss narrowed to $57.1M ($0.35/sh) from $73.5M ($0.45/sh) a year ago; adjusted EBITDA $88.8M.","Integrated Care revenue +9% to $374.4M; BetterHelp revenue +8% to $285.8M.","Operating cash flow $105.6M, free cash flow $68.0M; strong cash generation.","Q4 guidance: rev $658-683M, adj EBITDA $107-117M; FY23 rev $2.60-2.625B, adj EBITDA $320-330M.","CEO announces comprehensive operational review to drive efficiency and improve business performance."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1941888000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277929,"accession_number":"0001477449-23-000049","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc Health appoints Surgery Partners CEO Eric Evans to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Evans, CEO of Surgery Partners (SGRY), appointed to Teladoc Health board effective September 20, 2023.","Evans replaces retiring Senator William Frist, M.D.; will serve on compensation committee.","Evans brings experience scaling Surgery Partners to 180+ locations, over 50% revenue growth since 2019.","Board increased to ten members; Evans determined independent under NYSE standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277928,"accession_number":"0001477449-23-000005","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Health Q2 revenue $652M (+10% YoY); adj EBITDA $72.2M beats outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $652.4M (+10% YoY); Integrated Care $360.1M (+5%), BetterHelp $292.4M (+18%).","Net loss $65.2M ($0.40/share) vs $3.1B loss in Q2 2022 which included $3.03B goodwill impairment.","Adjusted EBITDA $72.2M (+54% YoY), exceeding expectations; operating cash flow $101.2M.","Q3 2023 guidance: revenue $650-$675M, adj EBITDA $72-$82M; full-year adj EBITDA $300-$325M.","U.S. Integrated Care members guided at ~86 million for Q3 and full year 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1281650000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295944,"accession_number":"0001104659-23-066013","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-05-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Teladoc Health shareholders approve new incentive plan and ESPP amendment; severance plan for execs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved the 2023 Incentive Award Plan, authorizing 8,250,000 shares for future equity grants.","ESPP amendment increases share reserve by 3,000,000 shares, removes evergreen clause, caps contributions at 15%.","Compensation Committee approved the Level 14 Severance Plan (effective June 1, 2023) for eligible executives.","Severance provides 6 months base salary (non-Change of Control) or 9 months plus 75% target bonus (Change of Control).","All nine director nominees elected; advisory vote on executive compensation passed (74.4M for vs 16.4M against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295943,"accession_number":"0001558370-23-006823","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q1 revenue $629M (+11% YoY); net loss $0.42/sh; guides Q2 rev $635-660M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $629.2M (+11% YoY); Integrated Care $350M (+5%), BetterHelp $279M (+21%).","Net loss $69.2M ($0.42/sh) vs $6.67B loss in Q1 2022 which included $6.6B goodwill impairment.","Adjusted EBITDA $52.8M (-3% YoY); Integrated Care segment adj. EBITDA +51% to $35.1M, BetterHelp -41% to $17.6M.","Q2 2023 guidance: rev $635-660M, adj. EBITDA $60-68M, net loss per share ($0.55)-($0.45).","Full year 2023 guidance: rev $2.575-2.675B, adj. EBITDA $285-325M, net loss per share ($1.70)-($1.25)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":629244000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316484,"accession_number":"0001558370-23-001751","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Health Q4 revenue up 15% to $637.7M; net loss of $3.81B on $3.77B goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $2.41B (+18% YoY); net loss $13.66B ($84.60/share) driven by $13.4B non-cash goodwill impairment.","Q4 adjusted EBITDA $94.1M (+22% YoY); full-year adjusted EBITDA $246.5M (-8% YoY).","BetterHelp segment Q4 revenue $277.0M (+29% YoY); Integrated Care Q4 revenue $357.1M (+6% YoY).","Full-year free cash flow $16.5M vs $130.1M in 2021; cash position $918.2M at Dec 31, 2022.","Q1 2023 revenue guidance $610-625M; full-year 2023 revenue $2.55-2.675B, adjusted EBITDA $275-325M."],"consensus_eps_estimate":null,"consensus_eps_actual":-84.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":2406840000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316483,"accession_number":"0001104659-23-004441","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-01-18T23:59:59+00:00","items":["2.05","9.01"],"status":"ready","headline":"Teladoc Health cuts workforce 6% (~300 roles), expects $17M in 2023 restructuring charges","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Layoffs affect ~300 non-clinician employees, ~6% of workforce; office space reductions in certain markets.","Q4 2022 pre-tax charges of $4.4M ($2M severance, $2.4M exit costs); expects ~$17M in charges in 2023.","Of 2023 charges, ~$10M are cash expenditures for workforce reductions; also expects $6M reduction in stock-based compensation.","CEO cites redundant roles from post-merger integration and need for balanced growth of revenue and profitability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316482,"accession_number":"0001104659-23-002066","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Teladoc pre-announces Q4 revenue $633-640M; FY22 revenue $2.403-2.410B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 total revenue guided $2.403B-$2.410B, including ~$1B from BetterHelp.","Q4 2022 revenue expected $633M-$640M; adjusted EBITDA outlook unchanged from prior guidance.","Preliminary, unaudited figures subject to completion of financial close and audit.","Company reaffirms adjusted EBITDA outlook consistent with Q3 2022 earnings release.","Management to present at 41st Annual J.P. Morgan Healthcare Conference on Jan 9, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-84.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":2406840000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334755,"accession_number":"0001104659-22-112474","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-10-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc Health appoints Laizer Kornwasser as President, Enterprise Growth & Global Markets","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laizer Kornwasser appointed President, Enterprise Growth & Global Markets effective Oct 24, 2022.","Compensation includes $500K base salary, $550K sign-on bonus, and $7M new-hire RSU award.","Annual equity grants of at least $4.5M expected in March 2023 and subsequent years.","Kornwasser will oversee US Group Health, International, Hospitals & Health Systems, and BetterHelp channels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":334754,"accession_number":"0001558370-22-015396","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-10-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Health Q3 revenue up 17% to $611.4M; net loss narrows to $73.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $611.4M (+17% YoY); net loss $73.5M ($0.45/sh) vs $84.3M loss prior year.","Adjusted EBITDA $51.2M, above high end of guidance; operating cash flow $63.0M.","Nine-month 2022 net loss $9.85B driven by non-cash goodwill impairment; revenue $1.77B (+20%).","CEO Jason Gorevic cited strong quarter and progress on whole-person care strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":-61.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1769131000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352172,"accession_number":"0001558370-22-011140","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Health reports Q2 revenue $592M (+18% YoY) but net loss $3.1B on $3.0B goodwill impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $592.4M (+18% YoY); net loss per share $19.22, mainly from $3.0B non-cash goodwill impairment.","Adjusted EBITDA $46.7M, down 30% YoY from $66.8M.","CEO Jason Gorevic cited solid results and Primary360 momentum but noted macroeconomic uncertainty.","Six-month revenue $1.16B (+21% YoY); net loss $9.78B."],"consensus_eps_estimate":null,"consensus_eps_actual":-60.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":1157729000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":352171,"accession_number":"0001104659-22-082400","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-07-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teladoc Health appoints Mike Waters as COO effective July 25, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Waters joins from Providence (EVP, Ambulatory Care Network) to oversee operations, member services, and supply chain.","Compensation includes $470K base salary, $775K sign-on bonus, target annual bonus of 75% of base.","New-hire equity award of ~$5M in RSUs vesting over 3 years; additional annual equity ~$4M expected.","Waters eligible for severance under Teladoc's Senior Leader Severance Plan with COC and non-COC provisions.","No family relationships or related-party transactions requiring disclosure under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369686,"accession_number":"0001104659-22-067619","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-06-02T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Teladoc shareholders approve 15% net long ownership special meeting right","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Certificate amendment enabling 15% net long holders to call special meetings approved and filed.","All 10 director nominees elected; say-on-pay passed with ~91% support.","Ratification of Ernst & Young as independent auditor for FY2022 approved.","Seventh Amended and Restated Certificate and Sixth Amended and Restated Bylaws effective June 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":369685,"accession_number":"0001558370-22-006090","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q1 net loss $6.67B on $6.6B goodwill impairment; cuts 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $565.4M (+25% YoY); net loss $6.67B due to $6.6B non-cash goodwill impairment ($41.11/sh).","Adjusted EBITDA $54.5M (-4% YoY); net loss per share $41.58 vs. $1.31 a year ago.","FY 2022 guidance revised: revenue $2.4-2.5B, adj. EBITDA $240-265M, net loss per share ($43.50)-($43.00).","D2C mental health hit by higher ad costs with lower yield; chronic condition sales cycles elongated.","Primary360 and stepped-care chronic programs launched on multiple new clients in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":-41.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":565350000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388821,"accession_number":"0001558370-22-001588","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-02-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q4 revenue $554M (+45% YoY); 2022 guidance $2.55-2.65B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $554.2M (+45% YoY); full year 2021 revenue $2.03B (+86% YoY).","Q4 net loss improved to $0.07 per share from $3.07 loss; full year net loss $2.73 per share.","Adjusted EBITDA Q4 $77.1M (+53% YoY); full year $267.8M (+111% YoY).","2022 revenue guidance $2.55-2.65B, representing 25-30% growth over 2021.","Full year cash from operations $194.0M vs ($53.5M) prior year, a positive swing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":2032707000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":388820,"accession_number":"0001104659-22-002506","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Teladoc Health pre-announces FY2021 revenue of approximately $2.03B","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Preliminary total revenue for year ended Dec 31, 2021 is about $2,030 million.","Revenue figure is unaudited and subject to change upon completion of financial close.","No other financial metrics or guidance updates were provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":2032707000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406764,"accession_number":"0001104659-21-140947","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Teladoc Health holds investor day; slide deck furnished without specific financial data in filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor day held on November 18, 2021 with slide presentation furnished as Exhibit 99.1.","Presentation content not reproduced in the filing; only forward-looking statement caution provided.","No new financial results, guidance, or strategic targets disclosed in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":406763,"accession_number":"0001558370-21-013611","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2021-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teladoc Q3 revenue up 81% YoY to $522M; updates FY2021 revenue outlook to $2.015-$2.025B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $84.3M ($0.53 per share) vs $35.9M loss ($0.43) in Q3 2020.","Adjusted EBITDA rose to $67.4M from $39.5M; total visits 3.9M (+37% YoY).","U.S. paid membership grew to 52.5M (+2% YoY); chronic care enrollment 0.725M.","New agreements with CVS Health and Centene for Primary360 primary care model.","2021 full-year revenue outlook raised to $2.015B-$2.025B."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":1478472000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":425770,"accession_number":"0001104659-21-117122","cik":1477449,"company_name":"Teladoc Health, Inc.","ticker":"TDOC","form_type":"8-K","filed_at":"2021-09-20T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Teladoc Health COO David Sides resigns effective Sept 21; reaffirms 2021 guidance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["COO David Sides resigns effective September 21, 2021, to pursue another employment opportunity.","No successor named; search for new COO presumably underway.","Company reaffirms Q3 and full-year 2021 guidance provided on July 27, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1280740417.5842185,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-09-20T23:59:59+00:00|425770"}